MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.01% | 8.42% | -19.47% | 24.71% | -25.83% |
| Gross Profit | -5.01% | -8.42% | 19.47% | -24.71% | 25.83% |
| SG&A Expenses | 6.68% | -66.37% | -74.16% | -7.02% | -19.49% |
| Depreciation & Amortization | -85.71% | -91.38% | -94.05% | -91.95% | -92.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.90% | -54.02% | -48.29% | -25.09% | -55.58% |
| Operating Income | -5.90% | 54.02% | 48.29% | 25.09% | 55.58% |
| Income Before Tax | 30.38% | 58.05% | 55.62% | 167.32% | 39.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.38% | 58.05% | 55.62% | 183.15% | 39.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.38% | 58.05% | 55.62% | 183.15% | 39.90% |
| EBIT | -5.90% | 54.02% | 48.29% | 25.09% | 55.58% |
| EBITDA | -6.17% | 54.04% | 48.32% | 25.07% | 55.64% |
| EPS Basic | 29.41% | 58.59% | 56.30% | 181.82% | 40.56% |
| Normalized Basic EPS | 30.19% | 58.73% | 55.95% | 27.94% | 40.45% |
| EPS Diluted | 29.41% | 58.59% | 56.30% | 181.82% | 40.56% |
| Normalized Diluted EPS | 30.19% | 58.73% | 55.95% | 27.94% | 40.45% |
| Average Basic Shares Outstanding | -1.64% | 0.00% | 2.20% | 1.24% | 1.27% |
| Average Diluted Shares Outstanding | -1.64% | 0.00% | 2.20% | 1.24% | 1.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |